HDM1005 vs ribupatide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline

HDM1005

Developed by Hangzhou Zhongmei Huadong Pharmaceutical

Phase 3 in Obesitypeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07502001 (registry estimate)

No aligned efficacy figure on record for this race.

ribupatide

Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals

Phase 3 in Obesitypeptide
Reliable signal

NCT06396429 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 567 participants. The sponsor reports weight loss of up to 17.7% with ribupatide, 16.3 percentage points more than placebo, with up to 88.0% of treated participants losing at least 5% of body weight, and describes the trial as positive.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2026 · NCT06974851 (registry estimate)

Reported efficacy

Percentage change from baseline in weight after 48 weeks of treatment (Baseline, Week 48); Proportion of subjects with weight loss of≥5% from baseline after 48 weeks of treatment (Week 48): Mean weight loss at Week 48 (treatment policy estimand): up to 17.7% with HRS9531 (16.3 percentage points placebo-adjusted); up to 88.0% of HRS9531-treated participants achieved at least 5% weight loss (met)

Result source: NCT06396429

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHDM1005ribupatide
Body weight, % change—Trial running · NCT07279194—Not posted · NCT06396429
Weight loss of 5% or more—Trial running · NCT07279194—Not posted · NCT06396429
Weight loss of 10% or more—Trial running · NCT07279194—Not posted · NCT06396429
Waist circumference, change (cm)—Trial running · NCT07279194—Not posted · NCT06396429

Body weight, % change

HDM1005
—Trial running · NCT07279194
ribupatide
—Not posted · NCT06396429

Weight loss of 5% or more

HDM1005
—Trial running · NCT07279194
ribupatide
—Not posted · NCT06396429

Weight loss of 10% or more

HDM1005
—Trial running · NCT07279194
ribupatide
—Not posted · NCT06396429

Waist circumference, change (cm)

HDM1005
—Trial running · NCT07279194
ribupatide
—Not posted · NCT06396429
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HDM1005: no structured comparison results are available for Obesity.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ribupatide

Weight 17.7% @ 48wk
percent change · % of baseline
No placebo or comparator arm
NCT06396429 · Phase 3 · sponsor-reported, not registry data
Weight Loss 5% 88%
responder rate · % of participants
No placebo or comparator arm
NCT06396429 · Phase 3 · sponsor-reported, not registry data

Type 2 Diabetes

Shared mechanism: GLP-1/GIP receptor (dual) · full Type 2 Diabetes pipeline

HDM1005

Developed by Hangzhou Zhongmei Huadong Pharmaceutical

Phase 3 in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2027 · NCT07394114 (registry estimate)

No aligned efficacy figure on record for this race.

ribupatide

Developed by Kailera Therapeutics under a licence from Jiangsu Hengrui Pharmaceuticals

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT06649344 · Phase 3 · completed

This phase 3 trial randomly assigned 884 adults with type 2 diabetes on metformin, with or without an SGLT2 inhibitor, to once-weekly ribupatide 4 mg, ribupatide 2 mg or semaglutide 1 mg, with open-label treatment. The primary measure was HbA1c change at week 36, tested for non-inferiority against semaglutide. The company reports that both doses were non-inferior (HbA1c -2.78% and -2.34% against -2.29%) and that 4 mg was statistically superior, so the result is met. The margin and confidence intervals were not published, and the figures come from the company's own release.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: February 2027 · NCT07060456 (registry estimate)

Reported efficacy

Change in HbA1c (from baseline to 36 weeks treatment): Change in HbA1c from baseline (efficacy estimand): maximum mean reduction of 2.67% with once-weekly ribupatide injection (4 mg and 2 mg) vs placebo (met)

Result source: NCT06650007

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointHDM1005ribupatide
HbA1c, change—Trial running · NCT07394114—Not posted · NCT06650007
Body weight, change (kg)—Trial running · NCT07394114—Not posted · NCT06650007
HbA1c below 7%—Trial running · NCT07394114—Not posted · NCT06650007
Fasting plasma glucose, change—Trial running · NCT07394114—Not posted · NCT06650007
3-point MACE (% with event)—Trial running · NCT07394114—Not posted · NCT06650007

HbA1c, change

HDM1005
—Trial running · NCT07394114
ribupatide
—Not posted · NCT06650007

Body weight, change (kg)

HDM1005
—Trial running · NCT07394114
ribupatide
—Not posted · NCT06650007

HbA1c below 7%

HDM1005
—Trial running · NCT07394114
ribupatide
—Not posted · NCT06650007

Fasting plasma glucose, change

HDM1005
—Trial running · NCT07394114
ribupatide
—Not posted · NCT06650007

3-point MACE (% with event)

HDM1005
—Trial running · NCT07394114
ribupatide
—Not posted · NCT06650007
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

HDM1005: no structured comparison results are available for Type 2 Diabetes.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

ribupatide
Primary, HbA1c change from baseline to week 36 (non-inferiority vs semaglutide 1 mg, efficacy estimand): ribupatide 4 mg -2.78%, 2 mg -2.34%, semaglutide -2.29%; non-inferiority achieved for both doses (margin and CI not published), and 4 mg statistically superior to semaglutide, met. NCT06649344 · Phase 3 · design grade: moderate · publication or press release
Change in HbA1c from baseline (efficacy estimand): maximum mean reduction of 2.67% with once-weekly ribupatide injection (4 mg and 2 mg) vs placebo NCT06650007 · Phase 3 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HDM1005's landscape · ribupatide's landscape